R. Fleischmann

2.3k total citations · 1 hit paper
38 papers, 1.5k citations indexed

About

R. Fleischmann is a scholar working on Rheumatology, Genetics and Hematology. According to data from OpenAlex, R. Fleischmann has authored 38 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Rheumatology, 12 papers in Genetics and 9 papers in Hematology. Recurrent topics in R. Fleischmann's work include Rheumatoid Arthritis Research and Therapies (25 papers), Chronic Lymphocytic Leukemia Research (12 papers) and Systemic Lupus Erythematosus Research (12 papers). R. Fleischmann is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (25 papers), Chronic Lymphocytic Leukemia Research (12 papers) and Systemic Lupus Erythematosus Research (12 papers). R. Fleischmann collaborates with scholars based in United States, United Kingdom and Japan. R. Fleischmann's co-authors include Carol A. Connell, Steven R. Ytterberg, Rebecca Germino, Andrea Shapiro, Cunshan Wang, Deepak L. Bhatt, Jose L. Rivas, Gary G. Koch, Ted R. Mikuls and Keith S. Kanik and has published in prestigious journals such as New England Journal of Medicine, Annals of the Rheumatic Diseases and Lara D. Veeken.

In The Last Decade

R. Fleischmann

37 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis

2022 963 citations R. Fleischmann, Carol A. Connell et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
R. Fleischmann United States	11	840	324	300	232	205	38	1.5k
Jose L. Rivas Spain	11	852 1.0×	306 0.9×	308 1.0×	240 1.0×	233 1.1×	27	1.4k
Kenneth Kwok United States	18	973 1.2×	283 0.9×	480 1.6×	202 0.9×	317 1.5×	60	1.6k
Marcel D. Posthumus Netherlands	20	671 0.8×	347 1.1×	215 0.7×	160 0.7×	149 0.7×	30	1.4k
Wenhui Xie China	22	533 0.6×	317 1.0×	127 0.4×	133 0.6×	233 1.1×	93	1.4k
Mercedes Alperí Spain	25	744 0.9×	595 1.8×	247 0.8×	79 0.3×	183 0.9×	91	1.3k
Jonathan S. Coblyn United States	21	1.2k 1.5×	443 1.4×	466 1.6×	88 0.4×	147 0.7×	34	2.1k
Dimitrios A. Pappas United States	19	900 1.1×	260 0.8×	234 0.8×	64 0.3×	100 0.5×	87	1.3k
Tracy Cardillo United States	9	547 0.7×	220 0.7×	252 0.8×	46 0.2×	200 1.0×	13	1.1k
Joy Schechtman United States	11	1.1k 1.3×	533 1.6×	421 1.4×	61 0.3×	146 0.7×	17	1.7k
M Haga Canada	8	1.2k 1.4×	255 0.8×	277 0.9×	90 0.4×	110 0.5×	10	1.6k

Countries citing papers authored by R. Fleischmann

Since Specialization

Citations

This map shows the geographic impact of R. Fleischmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Fleischmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Fleischmann more than expected).

Fields of papers citing papers by R. Fleischmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Fleischmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Fleischmann. The network helps show where R. Fleischmann may publish in the future.

Co-authorship network of co-authors of R. Fleischmann

This figure shows the co-authorship network connecting the top 25 collaborators of R. Fleischmann. A scholar is included among the top collaborators of R. Fleischmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Fleischmann. R. Fleischmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Emery, Paul, R. Fleischmann, Robert Wong, et al.. (2025). Association Between Abatacept Exposure Levels and Infection Occurrence in Patients With Rheumatoid Arthritis: Post Hoc Analysis of the AVERT-2 Study. The Journal of Rheumatology. 52(5). 426–435.

Burmester, Gerd R, et al.. (2024). POS0639 BENEFIT–RISK ANALYSIS OF UPADACITINIB VERSUS ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS AND HIGHER OR LOWER RISK OF CARDIOVASCULAR DISEASE. Annals of the Rheumatic Diseases. 83. 770–771. 1 indexed citations

Emery, Paul, Yoshiya Tanaka, Vivian P. Bykerk, et al.. (2023). Sustained Remission and Outcomes with Abatacept plus Methotrexate Following Stepwise Dose De-escalation in Patients with Early Rheumatoid Arthritis. Rheumatology and Therapy. 10(3). 707–727. 6 indexed citations

Emery, Paul, Yoshiya Tanaka, Vivian P. Bykerk, et al.. (2023). The trajectory of clinical responses in patients with early rheumatoid arthritis who achieve sustained remission in response to abatacept: subanalysis of AVERT-2, a randomized phase IIIb study. Arthritis Research & Therapy. 25(1). 67–67. 1 indexed citations

Huizinga, T., Ernest Choy, Amy Praestgaard, et al.. (2023). Clinical Efficacy of Sarilumab Versus Upadacitinib Over 12 weeks: An Indirect Treatment Comparison. Rheumatology and Therapy. 10(3). 539–550. 1 indexed citations

Fleischmann, R., Boulos Haraoui, Maya H Buch, et al.. (2022). Analysis of Disease Activity Metrics in a Methotrexate Withdrawal Study among Patients with Rheumatoid Arthritis Treated with Tofacitinib plus Methotrexate. Rheumatology and Therapy. 10(2). 375–386. 1 indexed citations

Fleischmann, R., Alan Friedman, Edit Drescher, et al.. (2022). Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a multicentre, double-blind, randomised, controlled, phase 2 trial. The Lancet Rheumatology. 4(6). e395–e406. 8 indexed citations

Conaghan, Philip G., Stanley Cohen, Gerd R Burmester, et al.. (2021). Benefit–Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis. Rheumatology and Therapy. 9(1). 191–206. 6 indexed citations

Pachaï, Chahin, Seán Connolly, Yoshiya Tanaka, et al.. (2020). THU0095 IMPACT OF BASELINE EROSION SCORE ON RESPONSE TO TREATMENT AND FUTURE RADIOLOGICAL DAMAGE IN AVERT-2, A RANDOMISED PHASE IIIB STUDY OF ABATACEPT IN MTX-NAÏVE, ANTI-CITRULLINATED PROTEIN ANTIBODY–POSITIVE (ACPA+) PATIENTS WITH EARLY RA. Annals of the Rheumatic Diseases. 79. 261–261. 2 indexed citations

10.

Fleischmann, R., Peter Winkle, Jeffrey N. Miner, et al.. (2018). Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study. RMD Open. 4(1). e000584–e000584. 37 indexed citations

11.

Charles‐Schoeman, Christina, Désirée van der Heijde, Gerd R Burmester, et al.. (2017). Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies. The Journal of Rheumatology. 45(2). 177–187. 16 indexed citations

12.

Fleischmann, R., Bradley M. Kerr, Li‐Tain Yeh, et al.. (2014). Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia. Lara D. Veeken. 53(12). 2167–2174. 81 indexed citations

13.

Mease, Philip J., R. Fleischmann, J. Wollenhaupt, et al.. (2014). 210. Effect of Certolizumab Pegol Over 48 Weeks on Signs and Symptoms in Patients with Psoriatic Arthritis with and Without Prior Tumor Necrosis Factor Inhibitor Exposure. Lara D. Veeken. 53(suppl_1). i137–i138. 14 indexed citations

14.

Østergaard, Mikkel, Paul Emery, Philip G. Conaghan, et al.. (2011). Golimumab and Methotrexate combinatation therapy significantly improves synovitis, osteitis and bone erosion compared to Methotrexate alone - A magnetic resonance imaging study of Methotrexate-naïve rheumatoid arthritis patients. Annals of the Rheumatic Diseases. 70(3). 261–262. 2 indexed citations

15.

Emery, P., R. Fleischmann, Désirée van der Heijde, et al.. (2011). GOLIMUMAB AND RADIOGRAPHIC PROGRESSION IN RHEUMATOID ARTHRITIS: RESULTS OF GO-BEFORE AND GO-FORWARD STUDIES. Lara D. Veeken. 50. 119–120. 1 indexed citations

16.

Emery, Paul, Désirée van der Heijde, Mikkel Østergaard, et al.. (2011). Exploratory analyses of the association of MRI with clinical, laboratory and radiographic findings in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 70(12). 2126–2130. 36 indexed citations

17.

Fleischmann, R.. (2010). The clinical efficacy and safety of certolizumab pegol in rheumatoid arthritis. Expert Opinion on Biological Therapy. 10(5). 773–786. 7 indexed citations

18.

Cohen, Stanley & R. Fleischmann. (2010). Kinase inhibitors: a new approach to rheumatoid arthritis treatment. Current Opinion in Rheumatology. 22(3). 330–335. 79 indexed citations

19.

Fleischmann, R., et al.. (2005). Long term safety of etanercept in elderly subjects with rheumatic diseases. Annals of the Rheumatic Diseases. 65(3). 379–384. 108 indexed citations

20.

Budiman‐Mak, Elly, et al.. (1994). Healing of NSAID-induced gastric ulcers with a synthetic prostaglandin analog (enprostil).. PubMed. 89(7). 1014–20. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact